This is a preview of subscription content, log in via an institution to check access.
Reference
Nguyen CTT, et al. A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer. European Journal of Health Economics : 6 Mar 2019. Available from: URL: https://doi.org/10.1007/s10198-019-01040-7
Rights and permissions
About this article
Cite this article
Reviewing evidence of cost effectiveness of erlotinib in NSCLC. PharmacoEcon Outcomes News 824, 27 (2019). https://doi.org/10.1007/s40274-019-5755-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5755-3